RLACX
Price
$29.88
Change
-$0.28 (-0.93%)
Updated
Nov 13 closing price
VSCIX
Price
$120.70
Change
-$0.59 (-0.49%)
Updated
Nov 13 closing price
Ad is loading...

RLACX vs VSCIX

Header iconRLACX vs VSCIX Comparison
Open Charts RLACX vs VSCIXBanner chart's image
Russell Inv US Small Cap Equity A
Price$29.88
Change-$0.28 (-0.93%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Index I
Price$120.70
Change-$0.59 (-0.49%)
VolumeN/A
CapitalizationN/A
RLACX vs VSCIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RLACX vs. VSCIX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLACX is a Buy and VSCIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 151B vs. RLACX (795M). VSCIX pays higher dividends than RLACX: VSCIX (1.43) vs RLACX (0.24). RLACX was incepted earlier than VSCIX: RLACX (16 years) vs VSCIX (27 years). RLACX is a more actively managed with annual turnover of: 80.00 vs. VSCIX (12.00). RLACX has a lower initial minimum investment than VSCIX: RLACX (0) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 32.13 vs. RLACX (25.88). VSCIX return over 5 years is better than : 59.15 vs. RLACX (7.34).
RLACXVSCIXRLACX / VSCIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years27 years-
Gain YTD15.27818.40483%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets795M151B1%
Annual Yield % from dividends0.241.4317%
Returns for 1 year25.8832.1381%
Returns for 3 years-26.377.14-369%
Returns for 5 years7.3459.1512%
Returns for 10 years-3.52128.63-3%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHVS20.150.31
+1.56%
Pharvaris NV
BOX34.670.43
+1.26%
BOX
TSCO278.75-0.44
-0.16%
Tractor Supply Company
XGN2.75-0.04
-1.43%
Exagen
AMTX4.11-0.51
-11.04%
Aemetis